Program
olverembatinib
Also written as “HQP1351”, “Olverembatinib” and “Olverembatinib 20mg”.
Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Leukemia, Myeloid, Chronic-Phase · Precursor Cell Lymphoblastic Leukemia-Lymphoma · Gastrointestinal Stromal Tumors · Leukemia, Myeloid, Accelerated Phase, led by Ascentage Pharma Group International.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ascentage Pharma Group International | 105 open or running | phase 3since Sep 4, 2023 | Jul 1, 2018 | Mar 31, 2027phase 3 · NCT06640361 |
Also a collaborator on its studies: HealthQuest Pharma.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 1, 2018First study: phase 1 study in Gastrointestinal Stromal TumorsFirst studyNCT03594422 · 100 planned · China
- Mar 12, 2019Phase 1 study in Leukemia, Myeloid, Chronic-PhaseNCT03882281 · 12 enrolled · China
- Mar 13, 20192 phase 2 studiesNCT03883100, NCT03883087
- Sep 18, 2019Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04260022 · 242 planned · United States, Canada
- Oct 11, 2019Phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04126707 · 6 enrolled · China
- Oct 11, 2019Phase 2 study in Leukemia, Myeloid, Chronic-PhaseNCT04126681 · 144 enrolled · China
- Sep 4, 2023Phase 3 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT06051409 · 350 planned · United States, Australia, China and more
- Oct 11, 2024Phase 3 study in GISTNCT06640361 · 40 planned · China
- Nov 19, 2025Phase 1 study in PharmacokineticNCT07282093 · 48 planned · China
Ahead
- Mar 31, 2027Primary completion: phase 3 study in GISTNCT06640361
- Dec 2027Primary completion: phase 1 study in Gastrointestinal Stromal TumorsNCT03594422
- Dec 31, 2027Primary completion: phase 3 study in Precursor Cell Lymphoblastic Leukemia-LymphomaNCT06051409
- Dec 27, 2029Primary completion: phase 1 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04260022
TargetBeta
“An orally bioavailable inhibitor of a variety of kinases, including the Bcr-Abl tyrosine kinase, the mast/stem cell growth factor receptor Kit (c-Kit), the serine/threonine protein kinase Akt (protein kinase B), and the extracellular signal-regulated kinase (ERK) with antineoplastic activity”NCIt, by rule
“Bcr/Abl fusion protein inhibitor”ChEMBL 37, by rule
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07282093Pharmacokinetic · China | 1 | Recruiting | Jun 30, 2026 | 48 |
| NCT06640361GIST · China | 3 | Recruiting | Mar 31, 2027 | 40 |
| NCT06051409Precursor Cell Lymphoblastic Leukemia-Lymphoma · United States, Australia, China and more | 3 | Recruiting | Dec 31, 2027 | 350 |
| NCT04126707Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China | 1 | Completed | Jan 13, 2020 | 6 |
| NCT04126681Leukemia, Myeloid, Chronic-Phase · China | 2 | Completed | Aug 1, 2024 | 144 |
| NCT04260022Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Canada | 1 | Recruiting | Dec 27, 2029 | 242 |
| NCT03883100Leukemia, Myeloid, Accelerated Phase · China | 2 | UNKNOWN | Apr 2024 | 23 |
| NCT03883087Leukemia, Myeloid, Chronic-Phase · China | 2 | UNKNOWN | May 2024 | 41 |
| NCT03882281Leukemia, Myeloid, Chronic-Phase · China | 1 | Completed | Nov 16, 2019 | 12 |
| NCT03594422Gastrointestinal Stromal Tumors · China | 1 | Recruiting | Dec 2027 | 100 |
How it is read
Names in the registry
- “HQP1351”, 5 entries
- “Olverembatinib”, 2 entries
- “Olverembatinib 20mg”, 1 entry
- “Ascentage Pharma HQP1351 bioavailable inhibitor”, 1 entry
- “[14C] HQP1351”, 1 entry
Codes read as this program: HQP1351.
Conditions, from the studies’ own filings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive, 3 studies
- Leukemia, Myeloid, Chronic-Phase, 2 studies
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 study
- Gastrointestinal Stromal Tumors, 1 study
- Leukemia, Myeloid, Accelerated Phase, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.